Federal rescheduling and 280E relief mark the most significant cannabis regulatory shift since 1970
Q1 2026 marked a potential turning point for the U.S. cannabis industry, with a significant federal regulatory development reshaping the financial and strategic outlook for operators. Capital markets responded, and deal activity shifted. This report examines what the changes mean for valuations, M&A, and competitive positioning across the cannabis landscape.
Market Trends & Operating Performance
Financial Performance & Valuation Insights
M&A Activity & Consolidation
Regulatory & Policy Developments
Complete the form below to instantly access the comprehensive Q1 2026 Cannabis Market Intelligence Report:
By downloading this report, you agree to receive future cannabis industry intelligence reports and related market insights from Houlihan Capital. Unsubscribe any time.
For over 25 years, Houlihan Capital has provided specialized financial services to cannabis businesses across cultivation, retail, processing, and ancillary services. Our team understands the unique valuation challenges, regulatory complexities, and strategic considerations that define success in this rapidly evolving industry.
Cannabis Services: Business Valuations | Fairness Opinions | Transaction Advisory | Exit Planning | Compliance-Ready Financial Analysis
Questions? Contact our cannabis specialists at info@houlihancapital.com or 312.450.8600
This content is for informational purposes only and does not constitute investment or legal advice. Always consult qualified professionals regarding cannabis business operations and compliance.
